4NCG

Discovery of Doravirine, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses

4NCG の概要

• エントリーDOI: 10.2210/pdb4ncg/pdb
• 分子名称: Reverse transcriptase/ribonuclease H, p51 RT, 3-chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl}oxy)benzonitrile, ... (4 entities in total)
• 機能のキーワード: hiv-1 reverse transcriptase, non-nucleoside inhibition, wild type rt transferase-inhibitor complex, hydrolase-inhibitor complex, transferase-inhhibitor, hydrolase-inhhibitor complex, transferase/inhhibitor, hydrolase/inhhibitor
• 由来する生物種: Human immunodeficiency virus 1; 詳細
• 細胞内の位置: Matrix protein p17: Virion (Potential). Capsid protein p24: Virion (Potential). Nucleocapsid protein p7: Virion (Potential). Reverse transcriptase/ribonuclease H: Virion (Potential). Integrase: Virion (Potential): P04585 P04585
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 117052.48

構造登録者

Yan, Y. (登録日: 2013-10-24, 公開日: 2014-02-12, 最終更新日: 2024-05-22)

主引用文献

Cote, B.,Burch, J.D.,Asante-Appiah, E.,Bayly, C.,Bedard, L.,Blouin, M.,Campeau, L.C.,Cauchon, E.,Chan, M.,Chefson, A.,Coulombe, N.,Cromlish, W.,Debnath, S.,Deschenes, D.,Dupont-Gaudet, K.,Falgueyret, J.P.,Forget, R.,Gagne, S.,Gauvreau, D.,Girardin, M.,Guiral, S.,Langlois, E.,Li, C.S.,Nguyen, N.,Papp, R.,Plamondon, S.,Roy, A.,Roy, S.,Seliniotakis, R.,St-Onge, M.,Ouellet, S.,Tawa, P.,Truchon, J.F.,Vacca, J.,Wrona, M.,Yan, Y.,Ducharme, Y.
Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.
Bioorg.Med.Chem.Lett., 24:917-922, 2014

PubMed Abstract: The optimization of a novel series of non-nucleoside reverse transcriptase inhibitors (NNRTI) led to the identification of pyridone 36. In cell cultures, this new NNRTI shows a superior potency profile against a range of wild type and clinically relevant, resistant mutant HIV viruses. The overall favorable preclinical pharmacokinetic profile of 36 led to the prediction of a once daily low dose regimen in human. NNRTI 36, now known as MK-1439, is currently in clinical development for the treatment of HIV infection.

PubMed: 24412110
DOI: 10.1016/j.bmcl.2013.12.070

実験手法

X-RAY DIFFRACTION (2.58 Å)